1
|
Schwartbeck B, Rumpf C, Hait R, Decker C, Janssen T, Romme K, Dübbers A, Küster P, Graepler-Mainka U, Hebestreit H, Van-Koningsbruggen-Rietschel S, Renner S, Wollschläger B, Naehrig S, Stehling F, Schlegtendahl A, Ballmann M, Junge S, Sutharsan S, Kahl B. 536 Not only 5–base pair deletions in the intergenic region of the intercellular adhesion operon, but also mutations in the repressor of the intercellular adhesion operon lead to a mucoid phenotype in Staphylococcus aureus residing in the airways of people with cystic fibrosis. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01226-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
Freyberg M, Bewig M, Bampi G, Rauscher R, Große-Onnebrink J, Sutharsan S, Hong J, Manfredi C, Sorscher E, Stehling F, Bobis I, Ballmann M, Ignatova Z. 646 Heterogeneity of cystic fibrosis transmembrane conductance regulator transcript expression levels in people with cystic fibrosis. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01336-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
3
|
Chmiel J, Barry P, Colombo C, De Wachter E, Fajac I, Mall M, McBennett K, McKone E, Mondejar-Lopez P, Quon B, Ramsey B, Robinson P, Sutharsan S, Ahluwalia N, Lu M, Moskowitz S, Prieto-Centurion V, Tian S, Waltz D, Weinstock T, Xuan F, Zelazoski L, Zhang Y, Polineni D. 185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00875-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
4
|
Dillenhöfer S, Gruber W, Stehling F, Blosch C, Olivier M, Sutharsan S, Welsner M, Brinkmann F. Körperliche Aktivität und motorische
Leistungsfähigkeit bei Kindern mit Cystischer Fibrose –
verbessern sie sich unter der Therapie mit
Elexacaftor-Tezacaftor-Ivacaftor. Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S Dillenhöfer
- St. Josef Hospital Universitätsklinikum Bochum, Klinik
für Kinder- und Jugendmedizin, Abteilung Kinderpneumologie und
Mukoviszidosezentrum, Bochum, Germany
| | - W Gruber
- Kinderklinik, Universität Duisburg-Essen, Pädiatrische
Pulmologie und Schlafmedizin, Mukoviszidosezentrum, Essen, Germany
| | - F Stehling
- Kinderklinik, Universität Duisburg-Essen, Pädiatrische
Pulmologie und Schlafmedizin, Mukoviszidosezentrum, Essen, Germany
| | - C Blosch
- Kinderklinik, Universität Duisburg-Essen, Pädiatrische
Pulmologie und Schlafmedizin, Mukoviszidosezentrum, Essen, Germany
| | - M Olivier
- Kinderklinik, Universität Duisburg-Essen, Pädiatrische
Pulmologie und Schlafmedizin, Mukoviszidosezentrum, Essen, Germany
| | - S Sutharsan
- Universitätsklinikum Essen – Ruhrlandklinik, Abteilung
für Lungenheilkunde, Mukoviszidosezentrum, Essen, Germany
| | - M Welsner
- Universitätsklinikum Essen – Ruhrlandklinik, Abteilung
für Lungenheilkunde, Mukoviszidosezentrum, Essen, Germany
| | - F Brinkmann
- St. Josef Hospital Universitätsklinikum Bochum, Klinik
für Kinder- und Jugendmedizin, Abteilung Kinderpneumologie und
Mukoviszidosezentrum, Bochum, Germany
| |
Collapse
|
5
|
Dillenhöfer S, Gruber W, Stehling F, Blosch C, Olivier M, Sutharsan S, Taube C, Mellies U, Welsner M, Brinkmann F. P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy? J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00538-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Rumpf C, Schwartbeck B, Hait R, Deiwick S, Decker C, Romme K, Dübbers A, Küster P, Graepler-Mainka U, Hebestreit H, van Koningsbruggen-Rietschel S, Renner S, Wollschläger B, Naehrig S, Sterling F, Schlegtendal A, Sutharsan S, Ballmann M, Junge S, Kahl B. ePS3.01 Preliminary results of an ongoing study, which determines the prevalence and possible impact of mucoid Staphylococcus aureus on lung disease of people with cystic fibrosis. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00299-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Seufert R, Sedlacek L, Kahl B, Hogardt M, Hamprecht A, Haase G, Gunzer F, Haas A, Grauling-Halama S, MacKenzie CR, Essig A, Stehling F, Sutharsan S, Dittmer S, Killengray D, Schmidt D, Eskandarian N, Steinmann E, Buer J, Hagen F, Meis JF, Rath PM, Steinmann J. Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany. J Antimicrob Chemother 2019; 73:2047-2053. [PMID: 29684150 DOI: 10.1093/jac/dky147] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 03/23/2018] [Indexed: 11/14/2022] Open
Abstract
Objectives Aspergillus fumigatus is the most prevalent filamentous fungus in the respiratory tract of patients with cystic fibrosis (CF). The aim of this prospective multicentre study was to investigate the prevalence of azole-resistant A. fumigatus (ARAF) in respiratory secretions from CF patients across Germany and to characterize ARAF isolates by phenotypic and molecular methods. Methods Twelve tertiary care centres from Germany participated in the study. In total, 2888 A. fumigatus isolates from 961 CF patients were screened for ARAF by using azole-containing agar plates. Antifungal susceptibility testing of isolates was performed by broth microdilution according to EUCAST guidelines. Analysis of mutations mediating resistance was performed using PCR and sequencing of the cyp51A gene. Furthermore, genotyping by microsatellite PCR was performed. Results Of a total of 2888 A. fumigatus isolates, 101 isolates from 51 CF patients were found to be azole resistant (prevalence per patient 5.3%). The Essen centre had the highest prevalence (9.1%) followed by Munich (7.8%), Münster (6.0%) and Hannover (5.2%). Most ARAF isolates (n = 89) carried the TR34/L98H mutation followed by eight G54E/R, one TR46/Y121F/T289A and one F219S mutation. In two isolates no mutation was found. Genotyping results showed no major clustering. Forty-five percent of CF patients with ARAF had previously received azole therapy. Conclusions This is the first multicentre study analysing the prevalence of ARAF isolates in German CF patients. Because of a resistance rate of up to 9%, susceptibility testing of A. fumigatus isolates from CF patients receiving antifungal treatment should be part of standard diagnostic work-up.
Collapse
Affiliation(s)
- R Seufert
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Nuremberg, Germany
| | - L Sedlacek
- Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany
| | - B Kahl
- Institute of Medical Microbiology, University Clinics Münster, Münster, Germany
| | - M Hogardt
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - A Hamprecht
- Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Cologne, Germany
| | - G Haase
- Clinical Laboratory and Diagnostic Services (LDZ), Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany
| | - F Gunzer
- Institute of Medical Microbiology and Hygiene, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - A Haas
- Max von Pettenkofer-Institute of Hygiene and Medical Microbiology, Ludwig-Maximilians-University Hospital, Munich, Germany
| | - S Grauling-Halama
- Department of Infectious Diseases, Medical Microbiology and Hygiene, Ruprecht-Karls University Heidelberg, Heidelberg, Germany
- Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - C R MacKenzie
- Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - A Essig
- Institute of Medical Microbiology and Hygiene, Ulm University Hospital, Ulm, Germany
| | - F Stehling
- Department of Pediatric Pulmonology and Sleep Medicine, University of Duisburg-Essen, Children's Hospital, Essen, Germany
| | - S Sutharsan
- Department of Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - S Dittmer
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - D Killengray
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - D Schmidt
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - N Eskandarian
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - E Steinmann
- Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research [a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI)], Hannover, Germany
- Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, Germany
| | - J Buer
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - F Hagen
- Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
- Department of Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands
| | - J F Meis
- Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
- Centre of Expertise in Mycology, Radboud University Medical Centre/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
- Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - P-M Rath
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - J Steinmann
- Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Nuremberg, Germany
| |
Collapse
|
8
|
Nash E, Brokaar E, Casey R, Castellani C, Cotton C, Doe S, Duckers J, Edenborough F, Faulkner R, Garavaglia L, Hadjiliadis D, Singh C, Sutharsan S, Taylor-Cousar J. WS12-2-1 Pregnancy outcomes in women with cystic fibrosis on ivacaftor - an international survey. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30186-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Straßburg S, Linker CM, Sutharsan S, Weinreich G, Taube C, Welsner M. P239 Influence of systemic antibiotic therapy on heart and respiratory rates during inpatient antibiotic treatment of adult cystic fibrosis patients using a new contactless measurement system (Vitalog®). J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30532-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Downey D, Flume P, Jain M, Fajac I, Schwarz C, Pressler T, Van Koningsbruggen-Rietschel S, Taylor-Cousar J, Horsley A, Sutharsan S, Miller J, Poirier G, Jiang J, Inoue T, Wilson S, Lee PS, Gilmartin G. WS06-1 Initial results evaluating combinations of the novel CFTR corrector PTI-801, potentiator PTI-808, and amplifier PTI-428 in cystic fibrosis subjects. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30148-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Gruber W, Tas T, Blosch C, Koerner-Rettberg C, Dillenberger S, Welsner M, Sutharsan S, Mellies U, Stehling F. WS08.5 Balance, flexibility and agility - additional aspects of physical fitness and trainability in children and adolescents with CF. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30165-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
12
|
Sutharsan S, Taylor-Cousar J, Lekstrom-Himes J, Wang L, Lu Y, Elborn JS. Efficacy and Safety of Tezacaftor/Ivacaftor in Patients Aged >= 12 Years With CF Homozygous for F508del-CFTR: A Randomized Placebo (PBO) -Controlled Phase 3 Trial. Pneumologie 2018. [DOI: 10.1055/s-0037-1619211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Sutharsan
- Department of Pulmonary Medicine, University Hospital Essen – Ruhrlandklinik, University Duisburg-Essen
| | | | | | - L Wang
- Vertex Pharmaceuticals Incorporated, MA, USA
| | - Y Lu
- Vertex Pharmaceuticals Incorporated, MA, USA
| | - JS Elborn
- Imperial College and Royal Brompton Hospital, London, UK
| |
Collapse
|
13
|
Gruber W, Tas T, Thra D, Benzrath S, Koerner-Rettberg C, Sutharsan S, Mellies U. WS04.4 Balance, flexibility and agility – additional aspects of physical fitness and trainability in children and adolescents with CF. J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30178-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Sutharsan S, Welsner M, Hillmann T, Mellies U, Teschler H. 177 Long-term efficacy and adherence of colistin dry powder inhalation (CDPI) at a large German CF adult unit – real world experience. J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30541-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Derichs N, Taylor-Cousar J, Tullis E, Davies J, Nazareth D, Downey D, Rosenbluth D, Fajac I, Malfroot A, Bakker M, Clancy J, Uluer A, Castellani C, Sermet-Gaudelus I, Ahrens R, Sutharsan S, Welte T, Gust T, Kaiser A, Hoffmann A, Ratjen F, Rowe S. EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study. J Cyst Fibros 2017. [DOI: 10.1016/s1569-1993(17)30276-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Enaami H, Werther S, Sutharsan S, Börner E, Kury A, Teschler H, Weinreich G, Aigner C, Welter S. Obstruktive Schlafapnoe: ein Risikofaktor für postoperative Komplikationen in der Thoraxchirurgie? Zentralbl Chir 2016. [DOI: 10.1055/s-0036-1587527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Benzrath S, Gruber W, Mellies U, Thomas T, Dustin T, Welsner M, Sutharsan S, Brinkmann F, Koerner-Rettberg C. ePS04.6 Barrier and barrier management in sports in cystic fibrosis (CF). J Cyst Fibros 2016. [DOI: 10.1016/s1569-1993(16)30219-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Welsner M, Sutharsan S, Hillmann T, Mellies U, Teschler H. 123 Colobreathe ® dry powder inhaler (CSDPI) – improved adherence due to personal guidance by a respiratory therapist. J Cyst Fibros 2016. [DOI: 10.1016/s1569-1993(16)30361-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Unger N, Simon A, Lahner H, Mellies U, Stehling F, Sutharsan S, Sommerwerck U, Teschler H, Kiewert C, Grasemann C, Hauffa BP, Führer D. Endocrine disorders in adolescents and young adults with cystic fibrosis. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Ray DE, Sutharsan S, Forshaw PJ. Actions of pyrethroid insecticides on voltage-gated chloride channels in neuroblastoma cells. Neurotoxicology 1997; 18:755-60. [PMID: 9339822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Pyrethroid insecticides have the potential to act at several sites in excitable tissues in addition to their primary effect on sodium channels. We have assessed one such site, the voltage gated chloride channel. Following our previous demonstration of actions of deltamethrin on the voltage-gated chloride channel in rats and in neuroblastoma cells, we examined the dose-response relationship for deltamethrin by patch clamp analysis of voltage-gated channels in partially differentiated NIE115 cells. Open channel probability (P0) was assessed in channels stepped from 0 to +20 mV for 10 seconds. Deltamethrin significantly decreased P0 by 0.237+/-0.070 at 10(-10) M and, although construction of a dose-response relationship was rendered difficult by the very low water solubility of the pyrethroids, a decrease of 0.968+/-0.140 was reached at the highest concentration tested, 10(-4) M. A second Type II pyrethroid cypermethrin also decreased P0, by 0.430+/-0.09 at 5 x 10(-6) M, but the Type I pyrethroid cismethrin produced a decrease of only 0.188+/-0.08 at 2 x 10(-5) M. These effects were seen in 340 pS conductance, calcium-independent channels. A sample of 9 calcium-dependent channels with a conductance of 225 pS failed to show any response to deltamethrin. We conclude that actions on calcium-independent voltage-gated chloride channels are likely to contribute significantly to type II pyrethroid toxicity.
Collapse
Affiliation(s)
- D E Ray
- Medical Research Council Toxicology Unit, Leicester, United Kingdom
| | | | | |
Collapse
|